A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme

References

• Buckingham SC, Campbell SL, Haas BR, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17(10 ):1269–1274. doi:10.1038/nm.245321909104
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17 ):1842–1850. doi:10.1001/jama.2013.28031924193082
   PubMed Web of Science ®Google Scholar
• Bernardi A, Braganhol E, Jager E, et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 2009;281(1 ):53–63. doi:10.1016/j.canlet.2009.02.01819286307
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10 ):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Chen Z, Wei X, Shen L, Zhu H, Zheng X. 20 (S)‐ginsenoside‐Rg3 reverses temozolomide resistance and restrains epithelial‐mesenchymal transition progression in glioblastoma. Cancer Sci. 2019;110(1 ):389.30431207
   PubMed Web of Science ®Google Scholar
• Sabelström H, Quigley D, Fenster T, et al. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Exp Cell Res. 2019;378:76–86. doi:10.1016/j.yexcr.2019.03.00330844389
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15 Suppl 2:ii1–56. doi:10.1093/neuonc/not15124137015
   PubMed Web of Science ®Google Scholar
• Klemen ND, Feingold PL, Goff SL, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2016;24(1 ):135–141.27638681
   PubMed Web of Science ®Google Scholar
• Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glioblastoma. Neuro-Oncology. 2014;16(11 ):1441–1458. doi:10.1093/neuonc/nou21225190673
   PubMed Web of Science ®Google Scholar
• Suryadevara CM, Verla T, Sanchez-Perez L, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(Suppl 1 ):S68. doi:10.4103/2152-7806.17002425722935
   PubMedGoogle Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1 ):125–135. doi:10.1007/s00262-012-1319-022847020
   PubMed Web of Science ®Google Scholar
• Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370(1 ):85–90. doi:10.1016/j.canlet.2015.10.00926477683
   PubMed Web of Science ®Google Scholar
• Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4 ):198–213. doi:10.1016/j.tcb.2014.11.00625540894
   PubMed Web of Science ®Google Scholar
• Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86(3 ):231–245. doi:10.1038/labinvest.370038916446705
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2 ):214–221. doi:10.1016/j.coi.2012.12.00323298609
   PubMed Web of Science ®Google Scholar
• van Malenstein H, Gevaert O, Libbrecht L, et al. A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma. Clin Cancer Res. 2010. doi:10.1158/1078-0432.CCR-1009-3274
   PubMed Web of Science ®Google Scholar
• Yau C, Sninsky J, Kwok S, et al. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res. 2013;15(5 ):R103. doi:10.1186/bcr356724172169
   PubMed Web of Science ®Google Scholar
• Ng SW, Mitchell A, Kennedy JA, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633 ):433–437. doi:10.1038/nature2059827926740
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2006;55(10 ):1294–1298. doi:10.1007/s00262-005-0102-x16315030
   PubMed Web of Science ®Google Scholar
• Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3 ):377–386. doi:10.1093/carcin/bgp01419136477
   PubMed Web of Science ®Google Scholar
• Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol. 2009;115(2 ):185–192. doi:10.1016/j.ygyno.2009.07.01519665763
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816 ):633–640. doi:10.1016/S0140-6736(11)61847-322257673
   PubMed Web of Science ®Google Scholar
• Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010;102(19 ):1496–1512. doi:10.1093/jnci/djq34320852124
   PubMedGoogle Scholar
• Balyasnikova IV, Wainwright DA, Solomaha E, et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. J Biol Chem. 2012;287(36 ):30215–30227. doi:10.1074/jbc.M112.37001522778273
   PubMed Web of Science ®Google Scholar
• De Rosa A, Pellegatta S, Rossi M, et al. A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One. 2012;7(12 ):e52113. doi:10.1371/journal.pone.005211323284888
   PubMed Web of Science ®Google Scholar
• Hsu KF, Shen MR, Huang YF, et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015;113(3 ):414–424. doi:10.1038/bjc.2015.25426158423
   PubMed Web of Science ®Google Scholar
• Lu X, Liu J, Cui P, et al. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. Am J Cancer Res. 2018;8(8 ):1564.30210924
   PubMed Web of Science ®Google Scholar
• Cuoco JA, Benko MJ, Busch CM, Rogers CM, Prickett JT, Marvin EA. Vaccine-based immunotherapeutics for the treatment of glioblastoma: advances, challenges, and future perspectives. World Neurosurg. 2018;120:302–315. doi:10.1016/j.wneu.2018.08.20230196171
   PubMed Web of Science ®Google Scholar
• Sayour EJ, McLendon P, McLendon R, et al. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64(4 ):419–427. doi:10.1007/s00262-014-1651-725555571
   PubMed Web of Science ®Google Scholar
• Dutoit V, Herold-Mende C, Hilf N, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain. 2012;135(4 ):1042–1054. doi:10.1093/brain/aws04222418738
   PubMedGoogle Scholar
• Azad TD, Razavi S-M, Jin B, Lee K, Li G. Glioblastoma antigen discovery—foundations for immunotherapy. J Neurooncol. 2015;123(3 ):347–358. doi:10.1007/s11060-015-1836-826045361
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2 ):165–228. doi:10.1007/s00134-012-2769-823361625
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269 ):pl1–pl1. doi:10.1126/scisignal.200408823550210
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5 ):401–404 doi:10.1094/PDIS-11-11-0999-PDN22588877
   PubMed Web of Science ®Google Scholar
• Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus. 2006;20(4 ):E1. doi:10.3171/foc.2006.20.4.E1
   PubMedGoogle Scholar
• Zanders ED, Svensson F, Bailey DS. Therapy for glioblastoma: is it working? Drug Discov Today. 2019;24:1193–1201. doi:10.1016/j.drudis.2019.03.00830878561
   PubMed Web of Science ®Google Scholar
• Karanikas V, Tsochas S, Boukas K, et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther. 2008;7(3 ):345–352. doi:10.4161/cbt.7.3.542418094614
   PubMed Web of Science ®Google Scholar
• Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108(5 ):963–971. doi:10.3171/JNS/2008/108/5/096318447714
   PubMed Web of Science ®Google Scholar
• Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(32 ):4105–4114. doi:10.1200/JCO.2012.47.418924101053
   PubMed Web of Science ®Google Scholar
• Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19(5 ):617–623. doi:10.1038/sj.onc.120335810698506
   PubMed Web of Science ®Google Scholar
• Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol. 2014;16(10 ):1304–1312. doi:10.1093/neuonc/nou04524723564
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18 ):4062–4072. doi:10.1158/1078-0432.CCR-15-042826059190
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26 ):2455–2465. doi:10.1056/NEJMoa120069422658128
   PubMed Web of Science ®Google Scholar
• Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro-Oncology. 2013;15(11 ):1568–1579. doi:10.1093/neuonc/not11724049111
   PubMed Web of Science ®Google Scholar
• Mikheev AM, Ramakrishna R, Stoll EA, et al. Increased age of transformed mouse neural progenitor/stem cells recapitulates age‐dependent clinical features of human glioma malignancy. Aging Cell. 2012;11(6 ):1027–1035. doi:10.1111/acel.1200422958206
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15 ):1527–1535. doi:10.1056/NEJMoa06590117429084
   PubMed Web of Science ®Google Scholar
• Ko JH, Ko EA, Gu W, Lim I, Bang H, Zhou T. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol Cancer. 2013;12(1 ):106. doi:10.1186/1476-4598-12-10624053408
   PubMedGoogle Scholar